Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026?
Key takeaways
- (NASDAQ:ELVN) also received a rating update from Clear Street on April 27.
- (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company with a focus on the discovery and development of small-molecule therapeutics.
- While we acknowledge the potential of ELVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026? Noor Ul Ain Rehman Mon, May 11, 2026 at 6:13 AM GMT+7 2 min read ELVN MRK Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The rating update came after Merck noted during its fiscal Q1 earnings call that it believes Terns’ TERN-701 major molecular response “will be north of 50% and within the confidence interval as had been publicly stated.” The firm believes the comments to be a positive for ELVN-001, adding that today’s “high-level quantification” only further supports the significant degradation.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) also received a rating update from Clear Street on April 27. The firm lifted the price target on the stock to $55 from $36, maintaining a Buy rating on the shares. The firm stated that it left meetings with management with increased conviction in ELVN-001 as a differentiated ATP-site binder for BCR-ABL1. For additional reference, Enliven Therapeutics, Inc. (NASDAQ:ELVN) reported in fiscal Q4 and full year 2025 earnings that it has a strong balance with $463 million in cash, cash equivalents, and marketable securities, which is anticipated to provide cash runway into the first half of 2029.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company with a focus on the discovery and development of small-molecule therapeutics. The company’s pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002.